Article

Jeff George appointed Division Head of Alcon

Novartis has appointed Jeff George division head of Alcon, effective May 1.

 

Basel, Switzerland-Novartis has appointed Jeff George as division head of Alcon Laboratories, effective May 1.

George-who is currently division head of Sandoz-succeeds Kevin Buehler, who is retiring after a 30-year career at Alcon. As part of the transition, Buehler will provide management and strategic support for the company.

Additionally, Richard Francis-a pharmaceuticals and biotechnology leader-has been appointed the division head of Sandoz, succeeding George. Francis joins Novartis from Biogen Idec, where he has held roles across several therapeutic areas in both Europe and the United States over his 13-year career with the company.

"The appointments of Jeff George as the new division head of Alcon, and of Richard Francis as new division head of Sandoz place two strong leaders at the helm of two leading Novartis businesses,” said Joseph Jimenez, chief executive officer of Novartis. “These new leaders will set the direction for the next phase of growth for our eye care and generics businesses, two of our core growth engines. Both Jeff and Richard have the vision and expertise to strengthen our market leading positions.

 

“I want to thank Kevin Buehler for his strong leadership and contributions to Alcon's success over the years, and for leading Alcon through the merger and integration with Novartis. He will be missed,” Jimenez continued.

As division head of Alcon, George will continue to serve as a member of the executive committee of Novartis (ECN).

Since joining Novartis in January 2007, George has held leadership positions in the vaccines and diagnostics division and the pharmaceuticals division, and became division head of Sandoz in December 2008. He holds an MBA from Harvard University, an MA from Johns Hopkins, and a BA from Carleton College.

As division head of Sandoz, Francis will become a member of the ECN. He most recently served as Biogen Idec's senior vice president, U.S. commercial operations. Francis previously held leadership roles across commercial and sales in Sanofi and Wyeth. Francis graduated from Manchester Metropolitan University.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.